PARP1 and ovarian carcinoma: These measures were later adapted to next generation sequencing and the sum of these scores is referred to as the HRD score10, which was recently approved by FDA as a companion diagnostic for prioritizing patients with ovarian cancer for PARP inhibitor therapy.